FDA says to stop taking weight loss pill after finding it can cause cancer

Eisai, a Japan-based drugmaker, said Feb. 13 it will remove its drug, Belviq, from the U.S. market after the FDA found an increased risk of cancer in people who took the weight loss drug. 

Belviq was developed by San Diego-based drugmaker Arena Pharmaceuticals and was approved by the FDA in 2012. Arena later sold it to Eisai, and the drugmaker has continued selling it in the U.S. market. 

The FDA said Feb. 13 it found an increased cancer risk linked to Belviq from a clinical trial that was started after the drug received approval. The agency recommended people stop using Belviq immediately and for it to be removed from the market. 

The FDA said the cancer risk increases the longer the drug is taken. 

Read the full news release here.

More articles on pharmacy: 
Why physicians are fighting BCBS plan requiring use of mail-order pharmacies
Foreign governments are using US research, manipulating drug prices, White House study claims
Chain drugstores under probe in Oklahoma after claims of inadequate pharmacy staffing

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months